Therapeutic Targeting of Ras Mutant Cancers - Stites, Edward C. (Salk Inst itute for Biological Studies, La Jolla,; Paskvan, Kendra (Pacific Northwes t University for Health Sciences, ; Kato, Shumei (University of California, San Diego Moores Cancer Cen
23,99 €
inkl. MwSt.

Versandfertig in über 4 Wochen
payback
12 °P sammeln
  • Broschiertes Buch

The KRAS oncogene is believed to be the most common single nucleotide variant oncogene in human cancer. Historically, efforts to target KRAS and the other RAS GTPases have struggled. More recently, efforts have focused on identifying and exploiting features unique to specific oncogenic mutations.

Andere Kunden interessierten sich auch für
Produktbeschreibung
The KRAS oncogene is believed to be the most common single nucleotide variant oncogene in human cancer. Historically, efforts to target KRAS and the other RAS GTPases have struggled. More recently, efforts have focused on identifying and exploiting features unique to specific oncogenic mutations.